Our results confirmed that ITGB4 expression in serum (median: 1.834 ng/mL, Q25–Q75: 0.904–2.573 ng/mL, p = 0.038, Figure S4A) and tissues (median: 0.019 fold, Q25–Q75: 0.013–0.032 fold, p < 0.0001; Figure S4B) of metastatic CRC patients (N = 41) was higher than that in serum (median: 1.408 ng/mL, Q25–Q75: 0.707–2.080 ng/mL, Figure S4A) and tissues (median: 0.009 fold, Q25–Q75: 0.006–0.017 fold, Figure S4B) of non‐metastatic CRC patients (N = 55). This evidence concerns the gene ITGB4 and colorectal carcinoma.